Clinical Trial Update: Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels [Phase 2]

View source ↗

Summary

A Phase 2 exploratory study of omalizumab (Xolair) in chronic obstructive pulmonary disease patients with elevated IgE levels has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: National Jewish Health | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: WITHDRAWN